Literature DB >> 11249977

Sinusitis -- overcoming bacterial resistance.

I Brook1.   

Abstract

Sinusitis is a major cause of illness in the USA, and represents a substantial economic burden. Treatment of this condition usually involves antibiotics and, where there is a strong suspicion of bacterial etiology, has a high rate of success. Accurate diagnosis depends upon clinical assessment, but only four specific symptoms have been shown to be independent predictors of sinusitis. Other diagnostic approaches such as analysis of a microbiological sample must be considered in cases failing initial treatment. The main factors in choosing antibiotic therapy are the likely infecting pathogens, bacterial antibiotic resistance and antibiotics' pharmacological profiles. Accurate diagnosis and careful consideration when choosing therapy for sinusitis will optimise the chances of achieving an early cure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11249977     DOI: 10.1016/s0165-5876(00)00457-2

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  3 in total

1.  [Rhinosinusitis guidelines--unabridged version: S2 guidelines from the German Society of Otorhinolaryngology, Head and Neck Surgery].

Authors:  B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; R Weber; K Hörmann
Journal:  HNO       Date:  2012-02       Impact factor: 1.284

2.  [Rhinosinusitis guidelines of the German Society for Otorhinolaryngology, Head and Neck Surgery].

Authors:  B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; K Hörmann
Journal:  HNO       Date:  2007-10       Impact factor: 1.284

3.  Induction of CXC chemokines in A549 airway epithelial cells by trypsin and staphylococcal proteases - a possible route for neutrophilic inflammation in chronic rhinosinusitis.

Authors:  F Sachse; C von Eiff; W Stoll; K Becker; C Rudack
Journal:  Clin Exp Immunol       Date:  2006-06       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.